Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023GlobeNewsWire • 07/31/23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European UnionGlobeNewsWire • 06/27/23
Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?Zacks Investment Research • 06/09/23
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/10/23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 05/10/23
Amicus Therapeutics to Present at the Bank of America 2023 Health Care ConferenceGlobeNewsWire • 05/02/23
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023GlobeNewsWire • 05/01/23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe DiseaseGlobeNewsWire • 04/26/23
Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis ProtocolBusiness Wire • 04/23/23
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe DiseasePRNewsWire • 03/28/23
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe DiseaseGlobeNewsWire • 03/27/23
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/23
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 03/01/23
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 02/27/23
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023GlobeNewsWire • 02/22/23